J&J Phase 3 : Apalutamide + Hormone Therapy Before & After Surgery Improves Prostate Cancer Outcomes
31/5 15:27
(RTTNews) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT) given for six months before and after prostate cancer surgery. The investigational regimen s...